NVSNovartis PharmaceuticalsRunning, no new patients
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer · Advanced Solid Tumors Harboring the KRAS G12C Mutation
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 25 (final count)
- Started
- Jun 8, 2026
- Main results expected
- Jun 11, 2029
- Fully finished
- Sep 11, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants receiving opnurasib as single agent or in combination with other study treatments
Measured over: Assessed up to approximately 3 years
Duration of exposure to study treatment
Measured over: Assessed up to approximately 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07468071 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC